100 related articles for article (PubMed ID: 8906133)
1. Topotecan hydrochloride for metastatic ovarian cancer.
Med Lett Drugs Ther; 1996 Oct; 38(986):96-7. PubMed ID: 8906133
[No Abstract] [Full Text] [Related]
2. Topotecan: an important new drug in the management of ovarian cancer.
Markman M
Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-1. PubMed ID: 9122736
[No Abstract] [Full Text] [Related]
3. Topotecan approved for cancer chemotherapy.
Am J Health Syst Pharm; 1996 Aug; 53(15):1763-4. PubMed ID: 8842305
[No Abstract] [Full Text] [Related]
4. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
ten Bokkel Huinink W; Carmichael J; Armstrong D; Gordon A; Malfetano J
Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-19-S5-25. PubMed ID: 9122738
[TBL] [Abstract][Full Text] [Related]
5. Topotecan in platinum- and paclitaxel-resistant ovarian cancer.
Swisher EM; Mutch DG; Rader JS; Elbendary A; Herzog TJ
Gynecol Oncol; 1997 Sep; 66(3):480-6. PubMed ID: 9299264
[TBL] [Abstract][Full Text] [Related]
6. Topotecan and the treatment of recurrent ovarian cancer: is there a role for granulocyte colony-stimulating factor?
Saltz L; Janik JE
Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-26-S5-30. PubMed ID: 9122740
[TBL] [Abstract][Full Text] [Related]
7. Second-line therapy.
Nurs Stand; 1997 Feb; 11(21):28. PubMed ID: 9110778
[No Abstract] [Full Text] [Related]
8. New options for the treatment of advanced ovarian cancer.
Dunton CJ
Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-2-S5-11. PubMed ID: 9122739
[TBL] [Abstract][Full Text] [Related]
9. [Ovarian cancer. The new chemotherapeutic agents].
Catimel G; Talon A
Soins; 1995 Oct; (599):20-2, 24-5. PubMed ID: 8701349
[No Abstract] [Full Text] [Related]
10. Topotecan and PML: the limits of pharmaceutical industry research.
Learned J
Notes Undergr; 1996 Sep; (No 33):1-3. PubMed ID: 11363913
[TBL] [Abstract][Full Text] [Related]
11. [Phase II clinical study of topotecan hydrochloride in patients with recurrent advanced ovarian cancer].
Li JD; Guan ZZ; Liu JH; Xin XY; Cui Y; Huang CJ; Liu FY; Song L; Bian ML; Zhou QH
Ai Zheng; 2002 Apr; 21(4):416-20. PubMed ID: 12452024
[TBL] [Abstract][Full Text] [Related]
12. Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials group.
Dark GG; Calvert AH; Grimshaw R; Poole C; Swenerton K; Kaye S; Coleman R; Jayson G; Le T; Ellard S; Trudeau M; Vasey P; Hamilton M; Cameron T; Barrett E; Walsh W; McIntosh L; Eisenhauer EA
J Clin Oncol; 2005 Mar; 23(9):1859-66. PubMed ID: 15699482
[TBL] [Abstract][Full Text] [Related]
13. Topotecan now available for HIV, PML research.
AIDS Treat News; 1995 Apr; (no 220):4. PubMed ID: 11362319
[TBL] [Abstract][Full Text] [Related]
14. Topotecan demonstrates significant activity in small-cell lung cancer.
Oncology (Williston Park); 1996 Mar; 10(3):422-3. PubMed ID: 8820456
[No Abstract] [Full Text] [Related]
15. Clinical trials referral resource. Trials of topotecan.
Cheson BD; Phillips PH; Arbuck SG
Oncology (Williston Park); 1995 Mar; 9(3):220, 224-6, 228. PubMed ID: 7669515
[No Abstract] [Full Text] [Related]
16. [Chemosensitivity testing of topotecan as second-line agent in chemotherapy of ovarian cancer].
Qian XL; Peng ZL; Liu SL
Ai Zheng; 2003 Dec; 22(12):1352-4. PubMed ID: 14693068
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer.
Seiden MV; Muggia F; Astrow A; Matulonis U; Campos S; Roche M; Sivret J; Rusk J; Barrett E
Gynecol Oncol; 2004 Apr; 93(1):229-32. PubMed ID: 15047241
[TBL] [Abstract][Full Text] [Related]
18. Clinical trials referral resource. Clinical trials with topotecan.
Cheson BD; Arbuck SG
Oncology (Williston Park); 1993 Feb; 7(2):49-51. PubMed ID: 8439468
[No Abstract] [Full Text] [Related]
19. [Topotecan--a new principle of effectiveness in oncology. 4th Salzburg Symposium on Quality of Life. 15-17 December 1995].
Geburtshilfe Frauenheilkd; 1996 Jun; 56(6 Suppl):1-6. PubMed ID: 9022377
[No Abstract] [Full Text] [Related]
20. [Single topotecan or in combination with other chemotherapeutic agents for 18 recurrent advanced ovarian cancer patients].
Li H; Liu L; Zhang W
Zhonghua Zhong Liu Za Zhi; 2001 Nov; 23(6):513-5. PubMed ID: 11859726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
